259 related articles for article (PubMed ID: 11976797)
21. Receptors for glucagon-like peptide-1(7-36) amide on rat insulinoma-derived cells.
Göke R; Conlon JM
J Endocrinol; 1988 Mar; 116(3):357-62. PubMed ID: 2832504
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
23. Signal transmission after GLP-1(7-36)amide binding in RINm5F cells.
Göke R; Trautmann ME; Haus E; Richter G; Fehmann HC; Arnold R; Göke B
Am J Physiol; 1989 Sep; 257(3 Pt 1):G397-401. PubMed ID: 2551182
[TBL] [Abstract][Full Text] [Related]
24. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.
Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL
J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells.
Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K
J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751
[TBL] [Abstract][Full Text] [Related]
26. Dexamethasone pretreatment of rat insulinoma cells decreases binding of glucagon-like peptide-1(7-36)amide.
Richter G; Göke R; Göke B; Arnold R
J Endocrinol; 1990 Sep; 126(3):445-50. PubMed ID: 2170555
[TBL] [Abstract][Full Text] [Related]
27. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.
Kiesewetter DO; Gao H; Ma Y; Niu G; Quan Q; Guo N; Chen X
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):463-73. PubMed ID: 22170321
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin inhibits glucagon-like peptide-1-induced insulin secretion and proliferation of RINm5F insulinoma cells.
Stark A; Mentlein R
Regul Pept; 2002 Oct; 108(2-3):97-102. PubMed ID: 12220732
[TBL] [Abstract][Full Text] [Related]
29. Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.
Rylova SN; Waser B; Del Pozzo L; Tönnesmann R; Mansi R; Meyer PT; Reubi JC; Maecke HR
J Nucl Med; 2016 Aug; 57(8):1282-8. PubMed ID: 27127218
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1(7-36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells.
Gallwitz B; Schmidt WE; Conlon JM; Creutzfeldt W
J Mol Endocrinol; 1990 Aug; 5(1):33-9. PubMed ID: 2168708
[TBL] [Abstract][Full Text] [Related]
31. A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas.
Medina-García V; Ocampo-García BE; Ferro-Flores G; Santos-Cuevas CL; Aranda-Lara L; García-Becerra R; Ordaz-Rosado D; Melendez-Alafort L
Nucl Med Biol; 2015 Dec; 42(12):911-6. PubMed ID: 26364504
[TBL] [Abstract][Full Text] [Related]
32. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity.
John H; Maronde E; Forssmann WG; Meyer M; Adermann K
Eur J Med Res; 2008 Feb; 13(2):73-8. PubMed ID: 18424366
[TBL] [Abstract][Full Text] [Related]
33. Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas.
Widmann C; Dolci W; Thorens B
Biochem J; 1995 Aug; 310 ( Pt 1)(Pt 1):203-14. PubMed ID: 7646446
[TBL] [Abstract][Full Text] [Related]
34. Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.
Selvaraju RK; Velikyan I; Asplund V; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Eriksson B; Korsgren O; Eriksson O
Nucl Med Biol; 2014 Jul; 41(6):471-6. PubMed ID: 24857864
[TBL] [Abstract][Full Text] [Related]
35. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
36. Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation.
Chepurny OG; Holz GG
Cell Tissue Res; 2002 Feb; 307(2):191-201. PubMed ID: 11845326
[TBL] [Abstract][Full Text] [Related]
37. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
[TBL] [Abstract][Full Text] [Related]
38. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
39. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
40. Stimulatory effects of glucagon-like peptides on human insulinoma cells and insulin-releasing clonal RINm5F cells.
Flatt PR; Shiber O; Hampton SM; Marks V
Diabetes Res; 1990 Feb; 13(2):55-9. PubMed ID: 1965428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
